Circulating CD28-KLRG1+CD8+ T cells as prognostic indicators in advanced NSCLC chemoimmunotherapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include ...
The Immune Atlas identifies immune signatures in MM, enhancing outcome prediction and guiding personalized therapies by ...
Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...
MedPage Today on MSN
CAR7 Gene Therapy Shows Promise in T-Cell ALL
The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...
When killer T cells of our immune system divide, they normally undergo asymmetric cell division (ACD): Each daughter cell inherits different cellular components, which drive the cells toward divergent ...
Left: UMAP projections of CD8⁺/WPRE⁺ (adoptive T cells) and CD8⁺/WPRE⁻ (endogenous T cells) cells mapped onto a reference TIL atlas reveal a reduced prevalence of exhausted CD8⁺ T cells and enrichment ...
Cells that are about to die send a signal to an executioner protein, but sometimes, those cells can fight back and regenerate ...
At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an investigational in vivo gene ...
Findings from a phase I trial (NCT04183166) evaluating TG4050, a neoantigen therapeutic vaccine, in patients with operable, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback